Related Experiment Video
Updated: Feb 11, 2026

Author Spotlight: Developing a Microfluidic Lung-on-Chip Model for In-Depth Study of Human Immune Response and Infection Mechanisms
Published on: May 31, 2024
Rituximab for auto-immune alveolar proteinosis, a real life cohort study
Berenice Soyez1,2,3, Raphael Borie4,5,6, Cedric Menard7
1Service de Pneumologie A, DHU FIRE, centre de référence constitutif des maladies pulmonaires rares, Hôpital Bichat, APHP, 46 rue Henri Huchard 75877 Paris CEDEX, 18, Paris, France.
Background:
Whole lung lavage is the current standard therapy for pulmonary alveolar proteinosis (PAP) that is characterized by the alveolar accumulation of surfactant. Rituximab showed promising results in auto-immune PAP (aPAP) related to anti-GM-CSF antibody.
Methods:
We aimed to assess efficacy of rituximab in aPAP in real life and all patients with aPAP in France that received rituximab were retrospectively analyzed.
Results:
Thirteen patients were included. No patients showed improvement 6 months after treatment, but, 4 patients (30%) presented a significant decrease of alveolar-arterial difference in oxygen after 1 year. One patient received lung transplantation and one patient was lost of follow-up within one year. Although a spontaneous improvement cannot be excluded in these 4 patients, improvement was more frequent in patients naïve to prior specific therapy and with higher level of anti-GM-CSF antibodies evaluated by ELISA. No serious adverse event was evidenced.
Conclusions:
These data do not support rituximab as a second line therapy for patients with refractory aPAP.
More Related Videos
Related Concept Videos
Half-life of a Reaction
Characteristics of Life
The Angiosperm Life Cycle
Alveoli and Alveolar Ducts
What is the Immune System?
The Tree of Life - Bacteria, Archaea, Eukaryotes

